# Effect of hyperlipidemia in the atherosclerotic patients on sex hormones

Msc. Ihsan Naji Attyha

Msc. Esam Mohammed Turki

Jasim Muhamed Husan

Technical Unstitute/Kufa – Iraq

#### **Abstract**

The current study was designed to explain the relationship of testosterone and estradiol levels with the serum lipid profile alteration . It has included the measurement of serum testosterone and estradiol levels in healthy subjects (40 males and 43 post – menopausal females) , atherosclerotics male (40) and post – menopausal (41) atherosclerotic females . Serum triglyceride , cholesterol , HDL- cholesterol , LDL-cholesterol and VLDL- cholesterol were also estimated in those individuals . The results revealed significant (p < 0.05) elevation of serum estradiol level in atheroselerotic males when compared with those of the control group,Estradiol also was found decreased significantly (p <0.05) when testosterone levels indicated a significant (p < 0.05) in atherosclerotic post-menopausal female when compared with control group . The results identified the details of serum lipid profile changes in conditions of different levels of sex steroids .

## Introduction

Initiatives seek to understand the relevance of sex steroids with the abnormalities of lipids and lipoprotines in details, this has been always the hope of biochemists. Hyperlipdimea is a serious medical problem worldwide. The frequent type of such abnormality is hyper cholesterolemia. It is the leading cause for development of ischeamic heart diseases (1). Hyper triglyceridemia is less common, but it is also a

URL: http://www.uokufa.edu.iq/journals/index.php/ajb/index

risky pathological condition. The consequences of this abnormality is pancratitis and steatosis (2).

Sex steroids are a subset of sex hormones that produce sex differences or support reproduction. They include estrogens, progesterones, and androgens. The major male androgen is testosterone (3,4).

In observational studies postmenopausal women using estrogen have been found to have a reduced risk of major clinical coronary disease and reduced cardiovascular disease mortality (5). However, a large randomized clinical trial of estrogen replacement therapy for secondary prevention of coronary heart disease in post menopausal women failed to demonstrate a redeuced rate of coronary heart disease events (6). Finally two studies examining the relation of estrogen replacement therapy to carotid atherosclerosis have yielded conflicting results (7, 8).

### Materials and methods

- Patients and control group

Eighty one atherosclerotic patient who attended the Al-Hakeem Hospital in the Najaf were enrolled in this study.

They were 40 males (55  $\pm$  10 y) , and 41 postmenopausal females (60  $\pm$  5 y) .

The control groups consisted of age matched 83 individuals . They were , 40 males (44  $\pm$  7.2 y) , and 43 postmenopausal females (60  $\pm$  5.2 y) . Blood samples were taken from the fasting atients and control group at 9 AM .

Atherosclerosis cases and controls were chosen on the basis of their average carotid artery ultrasound measurements . A women was considered postmenopausal if she had not menstruated in the last two years .

URL: http://www.uokufa.edu.iq/journals/index.php/ajb/index

Postmenopausal women were further classified as a having undergone surgical menopause if they had a bilateral oophorectomy. Natural menopause also described nonmenstruating women 55 years of age or older who had a hysterectomy and had at least one intact ovary (9).

## - Blood samples

Disposable syringes and needles were used for blood collection . Blood samples were obtained from patients and the control group by vein puncture . Sample were allowed to clot at  $37^{\circ}\text{C}$ , and then centrifuged at 3000xg for 10 minutes . Serum were stored at  $-20^{\circ}\text{C}$  until analysis of the hormone.

- Determination of serum estradiol and testosterons levels in patients and control groups

The principle assay combines and enzyme immunoassay competition method with a final detection (ELFA) .

Total cholesterol , triglyceride , and HDL- cholesterol was determined using commercially available kit (Bio Merieux-France) . LDL-cholesterol , and VLDL-cholesterol was calculated using the following formula that developed previously (10) , in which : TC = (HDL- cholesterol) + (VLDL- cholesterol) + (LDL-cholesterol).

VLDL- triglycerides concentration was determined by dividing triglycerides value obtained on 2.2 (11) when triglycerides concentrations are given in mmol/L.

# Biostatistical analysis

The results were expressed as mean  $\pm$  SD . Students t-test was used for assessment of the results . Significant variation was considered when the P value was than 0.05 .

URL: <a href="http://www.uokufa.edu.iq/journals/index.php/ajb/index">http://www.uokufa.edu.iq/journals/index.php/ajb/index</a>

## Results and discussion

The estimation of serum estradiol , and testosterone concentrations revealed significant (p < 0.05) elevations of estradiol in atherosclerotic males when compared with those of control group . Serum testosterone didn't show significant variation during a comparable elevation (table 1) .

In postmenopausal females estradiol was found to decrease significantly (p < 0.05) in the atherosclerotic females when compared with those of control group , while testosterone level was demonstrate to increase significantly (p < 0.05) to those of control group (Table 2) .

In atherosclerotic patients , males and postmenopausal females , cholesterol , triglycerides, LDL , and VLDL were elevated significantly (p < 0.001) for triglyceride and VLDL and(p < 0.01) for cholesterol and LDL-cholesterol) in comparison with those of the control group . HDL-cholesterol did't demonstrate significant change during a comparable evaluation (Table 3 , 4) .

Several studies have shown beneficial cardiovascular effects of exogenous estrogen, including lower body weight (12-14), increased high density lipoprotein (HDL) cholesterol and decreased low density lipoprotein (LDL) cholesterol (12, 14-16) levels, lower fasting insulin and glucose levels (10, 14), improved brachial artery blood flow (15) and regression of atherosclerotic plaques (16).

Prior to menopause , women have a mush lower risk of cardiovascular disease compared with men of the same age (17); However, menopause initiates a phase of increased risk (18). At the time of menopause compared with the premenopausal state, a women's endogenous hormonal milieu changes; there is a relative estrogen deficiency and relative increase in testosterone levels.

A weaker form of estrogen, estrone, continues to be synthesized as a result of peripheral conversion from adrenal androstendione in the fat

URL: http://www.uokufa.edu.iq/journals/index.php/ajb/index

, liver and kidney (19). Given what is known about the relation between estrogens , androgens and cardiovascular disease in women receiving estrogen replacement therapy , postmenopausal women with significant atherosclerosis and cardiovascular disease would be expected to have lower endogenous estrogen levels and higher endogenous androgen levels than those without significant atherosclerosis .

Studies examining the relation between endogenous postmenopausal hormone levels and cardiovascular disease have yielded conflicting results . Several studies have found no association between sex hormone levels and risk of death from cardiovascular disease (20-22) . However , two studies suggest a protective effect of higher androgen levels on cardiovascular disease in postmenopausal women (23, 24) .

An interesting point is that all serum lipid profile parameters are significantly changes in the stated population accept HDL- cholesterol concentration. The reason seems to be unclear and not fully understated it needs further clarification. Several reports have stated alterations in the HDL- cholesterol subclasses but the total function still remained constant (25).

Table (1). Serum estradiol and testosterone levels in control group and atherosclerotic males .

	Control group	Patients	P value
Estradiol	$29.42 \pm 19.37$	$39.17 \pm 24.15$	0.05
Testosterone	$3.76 \pm 1.89$	$3.70 \pm 2.74$	N.S.

URL: <a href="http://www.uokufa.edu.iq/journals/index.php/ajb/index">http://www.uokufa.edu.iq/journals/index.php/ajb/index</a>

Table (2). Serum estradiol and testosterone levels in control group and atherosclerotic postmenopausal females.

	Control group	Patients	P value
Estradiol	$25.91 \pm 23.23$	$32.05 \pm 30.72$	0.05
Testosterone	$0.55 \pm 0.11$	$0.61 \pm 0.60$	0.05

Table 3. Serum lipid profile in control group and atherosclerotic males

	Control group	Patients	P value
Triglycerides	$2.28 \pm 1.14$	$4.82 \pm 2.12$	0.001
Cholesterol	$5.22 \pm 2.20$	$6.95 \pm 2.28$	0.01
HDL-cholesterol	$0.97 \pm 0.30$	$0.76 \pm 0.64$	N.S
LDL-cholesterol	$3.63 \pm 1.80$	$4.42 \pm 2.22$	0.01
VLDL-cholesterol	$1.02 \pm 0.46$	$2.05 \pm 1.33$	0.001

Table 4. Serum lipid profile in control group and atherosclerotic postmenopausal females

	Control group	Patients	P value
Triglycerides	$1.55 \pm 0.61$	$3.99 \pm 1.89$	0.001
Cholesterol	$4.73 \pm 1.78$	$7.74 \pm 3.60$	0.01
HDL-cholesterol	$0.94 \pm 0.35$	$0.85 \pm 0.55$	N.S
LDL-cholesterol	$3.29 \pm 1.70$	$4.86 \pm 2.75$	0.01
VLDL-cholesterol	$0.71 \pm 0.20$	$0.85 \pm 0.80$	0.001

#### References

1- Carr, M. and Brunzell, J. (2004). Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabettes and familial combined byperlipidemia in coronary artery disease risk, J. Clin Endocrinol. Metab., 89: 2601-2607.

URL: http://www.uokufa.edu.iq/journals/index.php/ajb/index

- 2- Slisaf, M.; Nakou, K.; Liamis, G. and et. Al. (2000): Tamoxifen induced severe hypertriglyceridemia and pancereatitis, Ann. Oncol., 11: 1067-1069.
- 3- Frederikson, D.; Levy, R. and Less, R. (1967): Fat transport in lipoproteins: an integrated approach to mechanism and disorders, A Engl. J. Med., 276: 215-225.
- 4- Burger, H.; Dudley, E.; Bui, J. and et. Al. (2000): A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition, J. Clin. Endocrinol. Metab., 85: 2832-2838.
- 5- Stampfer MJ, Colditz GA, Willett WC, et. Al. (1991). Postmenopausal estrogen therapy cardiovascular disease. Ten-year follow up from the Health study . N Engl Med.; 325: 756-62.
- 6- Hulley S, Grady D, Bush T, et. Al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin Replacement study (HERS) Research Group. JAMA; 280: 605-13.
- 7- Nabulsi AA, Folsom AR, Szkol M, et. Al. (1996). No association of menopause and hormone replacement therapy carotid artery intimamedia thickness. Atherosclerotic Risk in Communities (ARIC) Study investigations. Circulaion; 94: 1857-63.
- 8- Manolio TA, Furberg CD, Shemanski, et. Al. (1993). Associations of menopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation; 88 (5 pt 1): 2163-71.
- 9- Szklo M, Cerhan J, Diez-Roux AV, et. Al. (1996). Estrogen replacement therapy and cognitive functioning in

URL: http://www.uokufa.edu.iq/journals/index.php/ajb/index

- Atherosclerosis Risk in Communities (ARIC) Stude. Am J Epidemiol; 144: 1048-57.
- 10- Bishop M. L., Laufen J.L., and Fody E.P., (1985). Clinical Chemistry, 1ed. Philadelphia, Lippincott Co..
- 11- Jackob, N.; Van Dennark, J. and Arch, P. (1960): Biochem. Biophysiology, 88:250-255.
- 12- Stevendon, J.; Crook, D. and Godsland, I. (1993): Influence of age and menopause status on serum lipids and lipoproteins in healthy women, Atherosclerotic, 98:83-90.
- 13- Haarbo J, Marslew U, Gotfredesen A, et. Al. 1991(. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause). Metabolism; 40: 1323-6.
- 14- Kritz- Silverstein D, Barrett-Connor E. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA; 275: 469.
- 15- Nabulsi AA, Folsom AR, White A, et. Al. (1993). Association of hormone replacement therapy with various cardiovascular risk factor in postmenopausal women. The Atherosclerotic Communities Study investigator. N Engl J Med; 328: 1069-75.
- 16- Vaziri SM, Evans JC, Larson MG, et. Al. (1995). The impact of female hormone usage on the lipid profile. The Framingham Offspring Study. Arch Intern Med; 153: 2200-6.
- 17- Koh kk, Blum A, Hathaway L, et. Al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women . Circulation; 100: 1851-7.
- 18- Akkad A, Hartshome T, Bell PR, et. Al. (1996) . Carotid plaque regression on estrogen replacement : a pilot study. Eur J Vasc Endovasc Surg 11: 347-8 .

URL: <a href="http://www.uokufa.edu.iq/journals/index.php/ajb/index">http://www.uokufa.edu.iq/journals/index.php/ajb/index</a>

- 19- Grodstein F, Manson J, Stampfer M. Postmenopausal hormone therapy. In Mnson JE, Ridker PM, Gaziano JM, et. Al., (1996).
   Eds. Prevention of myocardial infraction. Oxford United Kingdom: Oxford University Press, 413-30.
- 20- Schiff I. Menopause. In: Becker KL, ed. (1995). Principles and practice of endocrinology and metabolism. 2<sup>nd</sup> ed. Philadelphia, PA: J B Lippincott Company, 915-24.
- 21- Barrett- Connor E, Goodman- Gruen D. (1995). Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ; 311: 1193-6.
- 22- Goodman- Gruen D, Barrett- Connor E. (1996). A prospective study of sex hormone- binding globulin and fatal cardiovascular disease in Rancho Bernardo men and women. J Clin Endocrinol Metab; 81: 2999-3003.
- 23- Barrett- Connor E, Goodman- Gruen D, (1995). The epidiology of DHEAS and cardiovascular disease. Ann N Y Acad Sci.; 774: 259-70.
- 24- Haffner SM, Moss SE, Klein BE, et. Al. (1996). Sex hormones and DHEASO4 in relation to iischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic study of Diabetic Retinopathy. Diabetes Care; 19: 1045-50.
- 25- Bernini GP, Sgro M, Moretti A, et. Al. (199). Endogenous androgens and carotid intimal-n women. J Clin Endocrinol Metab. 84: 2008-12.
- 26- Kannel, W. and Gee, D. (2006): Lipids, diabetes and coronary heart disease, A m Heart J., 110: 1100.

URL: <a href="http://www.uokufa.edu.iq/journals/index.php/ajb/index">http://www.uokufa.edu.iq/journals/index.php/ajb/index</a>



تاثير فرط الشحوم لدى الاشخاص المصابين بتصلب الشرابين على الهرمونات الجنسية

## الخلاصة:

تم تصميم الدراسة الحالية لتوضيح من العلاقة بين مستويات كل من التستوستيرون والاسترادايول مع تغيرات الدهون المصلية . تضمن الدراسة تقديراً لمستويات التستو ستيرون والاسترادايول في اشخاص اصحاء (40 رجل و 43 امراءة بأعمار بعد انقطاع الطمث) . وذكور مصابين بتصلب الشرايين (41) وا ناث مصابات بتصلب الشرايين (41 باء مار بعد انقطاع الطمث) . فضلاً عن ذلك تم تقدير والكلسريدات الثلاثية للصلية المصلية للكولسترول والكولسترول في الاشخاص الاصحاء والمرضى . LDL الكليسريدات الثلاثية المصلية للكولسترول والكولسترول في الاشخاص الاصحاء والمرضى . لاسترادايول لدى الذكور للكولسترول والكولسترول في الاسترادايول نقصاً وألم مستوى الاسترادايول لدى الذكور المصابين بتصلب الشرايين عند مقارنتهم مع مجمو عة السيطرة واظهر الاسترادايول نقصاً مقارنتهم مع مجمو عة السيطرة . بينما اظهرت مستويات التستو ستيرون زيادة معنوية ( > p مقارنتهم مع مجمو عة السيطرة . بينما اظهرت دتائج تقدير الدهون المصلية زيادة الدهون المصابين بتصلب الشرايين عند المقارنة ب مجموعة السيطرة . ان الذتائج قد بينت بالتفصيل تغيرات الدهون المصلية في مستويات مختلفة من الهرمو نات الستيرويدية الجنسية .

URL: http://www.uokufa.edu.iq/journals/index.php/ajb/index